Komori
Kissei Pharmaceutical (4547) · InitiativeReframed

Advancing ESG/SDGs Management

First written in FY2020. 1 of 4 entries say "Restated". Latest entry: FY2025.

4entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020 – FY2022AdvancedFY20242020: 120202021: 020212022: 120222023: 020232024: 120242025: 12025
Same theme, other companies
Advancing Management Based on ESG Strategy and MaterialityA theme 115 companies write about · 0 as a headwind · 115 as a tailwind

Kissei Pharmaceutical moved to the "Worse" side of this theme in 2025, the same year as the typical company in this theme.

The whole theme swung hardest in 2017: 1 of 8 companies on the "Worse" side.

19 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 115 companies compared. The sentences above are computed from all 115.
Full recordFilings, disclosures and news, newest first
  1. FY2025ReframedAnnual report

    「To create greater synergies and further enhance corporate value, the Company decided to set common goals across the Group, systematically integrate its activities, and strengthen initiatives at the Group level. In May 2025, it reidentified 8 material issues to be addressed going forward.」

    The Company changed its framework from activities conducted separately by each group company to Group-wide management based on common goals, and reidentified materiality, reducing the number of items from 15 to 8.
  2. FY2024AdvancedAnnual report

    「The Company classified materiality related to business activities into the development and provision of socially useful products, a stable supply of high-quality products, and communication with healthcare professionals and patients. Materiality related to the management foundation was classified into strengthening and enhancing governance, creating a rewarding workplace, environmental initiatives, and social contribution as a good corporate citizen. From these categories, the Company identified 15 specific material issues.」

    The Company organized sustainability into 7 categories and 15 material issues, establishing a framework for setting KPIs and managing progress.
  3. FY2022RestatedAnnual report

    「The Company will promote ESG/SDGs management while maintaining good relationships with stakeholders and further strengthening its governance structure.」

    The Company has reaffirmed stakeholder relations, stronger governance, and the promotion of ESG/SDGs management as issues in strengthening the management foundation under PEGASUS.
  4. FY2020First statedAnnual report

    「The Company will promote ESG/SDGs management while maintaining good relationships with stakeholders and further strengthening its governance structure.」

    For the first time, the Company explicitly identified the promotion of ESG/SDGs management as an issue in strengthening the management foundation under the new 5-year medium-term management plan, “PEGASUS.”
Moved together

"Securing Profitability and Expanding the Healthcare Business" moved the same way as this thread, in the same document, in 2 of its 4 moves.

22★12
  1. ★This thread
  2. 1Securing Profitability and Expanding the Healthcare Business2×
  3. 2Preparation for TCFD Disclosure on Climate Change Risks2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Advancing ESG/SDGs Management | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori